40 completed, 21 recruiting, 8 active not recruiting, 8 unknown. 28 Phase 1, 22 Phase 2, 17 Not applicable, 4 Phase 3, 2 Phase 4.
Follow Appendiceal Neoplasms: new trials by email Literature Review of Appendiceal Neoplasms trials Research Report on Appendiceal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) - Peritoneal Carcinomatosis | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2026-08-05 | 2026-09-16 |
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC) Modified early post-operative intraperitoneal chemotherapy (mEPIC) - Peritoneal Carcinomatosis, Appendiceal Neoplasms | Phase 2 | Recruiting | Ciusss de L'Est de l'Île de Montréal | 25 | 2026-05-01 | 2026-05-14 |
| Molecular Profiling for Risk Stratification in Appendiceal Cancer DNA Methylation Profiling, m6A Epitranscriptomic Profiling - Appendiceal Cancer, Appendiceal Adenocarcinoma | Recruiting | City of Hope Medical Center | 400 | 2026-05-01 | 2026-06-29 | |
| A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis Mass-based response testing (MRT) - Appendiceal Cancer, Colorectal Adenocarcinoma | Not applicable | Recruiting | Yale University | 20 | 2026-02-17 | 2026-07-21 |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays PAGODA algorithm, Oxaliplatin, Folinic Acid - Ampulla of Vater Carcinoma, Appendix Carcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 420 | 2026-02-13 | 2026-10-02 |
| The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry Appendix Cancer, Pseudomyxoma Peritonei | Recruiting | Appendix Cancer Pseudomyxoma Peritonei Research Foundation | 10000 | 2026-02-02 | 2026-08-17 | |
| Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) CYTALUX™ (pafolacianine) - Gastrointestinal Cancer, Gastric Cancer | Phase 4 | Recruiting | Cedars-Sinai Medical Center | 15 | 2025-09-05 | 2025-09-15 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-15 |
| Target-specific immunoPET Imaging of Digestive System Carcinoma [68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4 - Malignancy, Digestive Cancer | Not applicable | Recruiting | RenJi Hospital | 400 | 2024-12-04 | 2025-12-31 |
| EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. EQUITY GI - Gastrointestinal Cancer, Colon Cancer | Not applicable | Recruiting | Case Comprehensive Cancer Center | 200 | 2024-12-01 | 2026-09-15 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Molecular Characterisation of Appendiceal Cancer Retrospective tissue sample analysis - Appendiceal Cancer | Recruiting | The Christie NHS Foundation Trust | 100 | 2024-02-04 | 2025-01-01 | |
| Intraperitoneal LSTA1 in CRS-HIPEC CRS-HIPEC + LSTA1, CRS-HIPEC alone - Colorectal Cancer, Ovarian Carcinoma | Phase 1 | Withdrawn | University of California, San Diego | 2023-11-30 | 2024-08-20 | |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) Ablative local therapy - Small Bowel Cancer, Colorectal Cancer | Not applicable | Recruiting | University of California, Davis | 300 | 2023-10-05 | 2026-07-02 |
| Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer FOX dose-escalation algorithm - Colorectal Cancer, Esophagus Cancer | Not applicable | Recruiting | Dartmouth-Hitchcock Medical Center | 36 | 2023-07-14 | 2026-06-22 |
| Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix Neoplasms, Appendix Cancer | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1000 | 2023-05-01 | 2024-07-30 | |
| Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma Surufatinib, Sintilimab, Capecitabine - Adenocarcinoma of Small Intestine, Appendix Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2023-02-01 | 2025-12-17 |
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer PIPAC with Nal-IRI - Peritoneal Carcinomatosis, Peritoneal Metastases | Phase 1 | Active not recruiting | University Hospital, Ghent | 45 | 2022-11-21 | 2026-07-13 |
Showing 20 of 85. Sign in to see all of them.
Stomach Neoplasms (39) · Colonic Neoplasms (36) · Colorectal Neoplasms (36) · Pancreatic Neoplasms (34) · Rectal Neoplasms (31) · Esophageal Neoplasms (29) · Gallbladder Neoplasms (25) · Bile Duct Neoplasms (22) · Anus Neoplasms (21) · Carcinoma, Hepatocellular (21) · Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (16) · Breast Neoplasms (15) · Peritoneal Neoplasms (14)
Cecal Diseases (85) · Digestive System Diseases (85) · Gastrointestinal Diseases (85) · Intestinal Diseases (85) · Cecal Neoplasms (84) · Digestive System Neoplasms (84) · Intestinal Neoplasms (83) · Neoplasms by Site (83) · Gastrointestinal Neoplasms (73) · Neoplasms (65) · Colonic Diseases (61) · Rectal Diseases (59) · Neoplasms by Histologic Type (47) · Neoplasms, Glandular and Epithelial (46) · Endocrine Gland Neoplasms (43)
Mitomycin (11) · Oxaliplatin (11) · Hyperthermic Intraperitoneal Chemotherapy (7) · Leucovorin (7) · Fluorouracil (6) · Irinotecan (6) · Capecitabine (4) · Cisplatin (4) · Cetuximab (3) · Cytoreduction Surgical Procedures (3) · Doxorubicin (3) · Surveys and Questionnaires (3) · Biopsy (2) · Drug Therapy (2) · Floxuridine (2)
National Cancer Institute (NCI) (9) · Wake Forest University Health Sciences (6) · City of Hope Medical Center (3) · Dartmouth-Hitchcock Medical Center (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Alliance for Clinical Trials in Oncology (2) · Case Comprehensive Cancer Center (2) · Cedars-Sinai Medical Center (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Mercy Medical Center (2) · NYU Langone Health (2) · Revolution Medicines, Inc. (2) · Travera Inc (2)
United States (65) · France (6) · Netherlands (4) · Australia (3) · Canada (3) · China (3) · Italy (3) · Spain (3) · Belgium (2) · Germany (2) · Poland (2) · Puerto Rico (2) · Singapore (2) · South Korea (2) · Argentina (1)
Andrew M Blakely, M.D. (2) · Dominique Elias, MD (2) · Franco M. Muggia, MD (2) · Revolution Medicines, Inc. (2) · Alexandre Brind'Amour, MD (1) · Amit Mahipal, MBBS (1) · Andreana N Holowatyj, PhD, MSCI (1) · Anthony W. Tolcher, MD (1) · Armando Sardi, M.D. (1) · Armando Sardi, MD (1) · Bradley Switzer, MD (1) · Brennan Spiegel, MD, MSHS (1) · Bruce Bissonnette, MD (1) · David R. Spriggs, MD (1) · Deborah Shelton (1)
PMID 11919233, PMID 12115365, PMID 12393999, PMID 14981738, PMID 16849762, PMID 18470481, PMID 18493824, PMID 19490638, PMID 19690306, PMID 22480131, PMID 23844722, PMID 25681217, PMID 27020837, PMID 28892212, PMID 29048177, PMID 29098385, PMID 29149611, PMID 30473706, PMID 30705736, PMID 31352425, PMID 31874901, PMID 32029830, PMID 32343238, PMID 32572849, PMID 33544279, PMID 34613617, PMID 34757489, PMID 36410913, PMID 37261831, PMID 37590355, PMID 37993560, PMID 40056080, PMID 40172884, PMID 40779182, PMID 41344351, PMID 42384131
P30CA016087 (2), P30CA033572 (2), P30CA068485 (2), 2017 (1), K01AT008219 (1), P01CA087971 (1), P30CA012197 (1), P30CA013330 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA023108 (1), P30CA043703 (1), P30CA044579 (1), P30CA093373 (1)